Ki8751 is primarily used in research settings to study cellular signaling pathways, particularly those involving angiogenesis and cancer progression. It functions as a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), which plays a critical role in the formation of new blood vessels. By blocking VEGFR-2, Ki8751 helps researchers understand the mechanisms of tumor growth and metastasis, providing insights into potential therapeutic strategies for cancer treatment. Additionally, it is utilized in preclinical studies to evaluate its efficacy in inhibiting angiogenesis, which is essential for developing anti-cancer drugs. Its application extends to exploring its effects on other VEGFR-related diseases, such as macular degeneration and inflammatory conditions.